2. Search Result
Search Result
Results for "

Antithrombotic Agent

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

3

Biochemical Assay Reagents

2

Peptides

3

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-U00383
    Rafigrelide

    3,3-Dimethylanagrelide

    		 Others Cardiovascular Disease
    Rafigrelide is a platelet-lowering agent, and also has antithrombotic properties.
    Rafigrelide
  • HY-101054
    NQ301
    1 Publications Verification

    		 Thrombin Cardiovascular Disease
    NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC50 of 10 mg/mL.
    NQ301
  • HY-105559A
    Viquidil hydrochloride

    Quinotoxine hydrochloride

    		 Others Cardiovascular Disease
    Viquidil hydrochloride (Quinotoxine hydrochloride), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil hydrochloride shows antithrombotic activity .
    Viquidil hydrochloride
  • HY-117824
    L-703014

    		Others Others
    L-703014 is a fibrinogen receptor antagonist, with the IC50 of 94 nM, that acts as a novel parenteral and potential oral antithrombotic agent .
    L-703014
  • HY-106932
    L-734217

    		Integrin Others Cardiovascular Disease
    L-734217 is an orally active and potent fibrinogen receptor antagonist and an antithrombotic agent. L-734217 is excreted largely by the renal route and partly into the bile in dogs. L-734217 is promising for research of thrombotic disorders .
    L-734217
  • HY-19052
    Trombodipine

    PCA-4230

    		 Others Cardiovascular Disease
    Trombodipine is an antithrombotic agent.
    Trombodipine
  • HY-106115
    Vintoperol

    RGH 2981; RT-3003

    		 Others Cardiovascular Disease
    Vintoperol (RGH 2981; RT-3003) is a potent and orally active antithrombotic agent. Vintoperol interferes with platelet aggregation and shows antithrombotic effects .
    Vintoperol
  • HY-105919
    Naroparcil

    		Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil
  • HY-105559
    Viquidil

    Quinotoxine

    		 Others Cardiovascular Disease
    Viquidil (Quinotoxine), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil shows antithrombotic activity .
    Viquidil
  • HY-P5889
    Thrombin receptor peptide ligand

    		Thrombin Cardiovascular Disease
    Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .
    Thrombin receptor peptide ligand
  • HY-125615
    DMP 728 methanesulfonate

    		Glycoprotein VI Cardiovascular Disease Others
    DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .
    DMP 728 methanesulfonate
  • HY-110043
    (±)-Clopidogrel hydrochloride

    		Others Cardiovascular Disease
    (±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors .
    (±)-Clopidogrel hydrochloride
  • HY-B1271
    Sulfinpyrazone

    G-28315

    		 Endogenous Metabolite Inflammation/Immunology
    Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .
    Sulfinpyrazone
  • HY-112624P
    Dextran T500 (MW 500,000)

    Dextran 500; Dextran D500; Dextran T500(MW 440000-560000)

    		 Biochemical Assay Reagents Others
    Dextran T500 MW 500,000 (Dextran 500; Dextran D500; Dextran T500 MW 440000-560000) is a polymer of anhydroglucose with the average molecular weight of 500,000. Dextran T500 MW 500,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
    Dextran T500 (MW 500,000)
  • HY-112624D
    Dextran T60 (MW 60,000)

    Dextran 60; Dextran D60; Dextran T60(MW 54000-66000)

    		 Biochemical Assay Reagents Others
    Dextran T60 MW 60,000 (Dextran 60; Dextran D60; Dextran T60 MW 54000-66000) is a polymer of anhydroglucose with the average molecular weight of 60,000. Dextran T60 MW 60,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
    Dextran T60 (MW 60,000)
  • HY-112624Q
    Dextran T800 (MW 800,000)

    Dextran 800; Dextran D800; Dextran T800(MW 750000-850000)

    		 Biochemical Assay Reagents Others
    Dextran T800 MW 800,000 (Dextran 800; Dextran D800; Dextran T800 MW 750000-850000) is a polymer of anhydroglucose with the average molecular weight of 800,000. Dextran T800 MW 800,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
    Dextran T800 (MW 800,000)
  • HY-119410
    Linotroban

    HN11500

    		 Prostaglandin Receptor Cardiovascular Disease
    Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .
    Linotroban
  • HY-129496
    NP-313

    		Thrombin Cardiovascular Disease
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
    NP-313
  • HY-B1271R
    Sulfinpyrazone (Standard)

    		Endogenous Metabolite Inflammation/Immunology
    Sulfinpyrazone (Standard) is the analytical standard of Sulfinpyrazone. This product is intended for research and analytical applications. Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .
    Sulfinpyrazone (Standard)
  • HY-163645
    P2Y12 antagonist 1

    		P2Y Receptor Cardiovascular Disease
    P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent .
    P2Y12 antagonist 1
  • HY-106784
    Ajoene

    		Fungal Apoptosis Infection Cancer
    Ajoene, a garlic-derived compound, is an antithrombotic and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities .
    Ajoene
  • HY-111755
    Oral antiplatelet agent 1

    		P2Y Receptor Cardiovascular Disease
    Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
    Oral antiplatelet agent 1
  • HY-17459
    Clopidogrel hydrogen sulfate
    Maximum Cited Publications
    22 Publications Verification

    (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate

    		 Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate
  • HY-115911
    GPVI antagonist 2

    		Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
    GPVI antagonist 2
  • HY-115912
    GPVI antagonist 3

    		Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
    GPVI antagonist 3
  • HY-137227
    15(R)-PTA2

    15(R)-Pinanethromboxane A2

    		 Others Cardiovascular Disease
    15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
    15(R)-PTA2
  • HY-17459S
    Clopidogrel-d3 hydrogen sulfate

    (S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate

    		 P2Y Receptor Cytochrome P450 Cardiovascular Disease
    Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
    Clopidogrel-d3 hydrogen sulfate
  • HY-17459R
    Clopidogrel hydrogen sulfate (Standard)

    (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)

    		 Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate (Standard)
  • HY-129611
    Bromelain

    		Apoptosis Inflammation/Immunology Cancer
    Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
    Bromelain
  • HY-10274
    Dabigatran etexilate
    3 Publications Verification

    BIBR 1048

    		 Thrombin Cardiovascular Disease
    Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate
  • HY-10274A
    Dabigatran etexilate mesylate
    3 Publications Verification

    BIBR 1048MS; Dabigatran etexilate methanesulfonate

    		 Thrombin Cardiovascular Disease
    Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate mesylate
  • HY-10274AR
    Dabigatran etexilate mesylate (Standard)

    		Thrombin Cardiovascular Disease
    Dabigatran etexilate (mesylate) (Standard) is the analytical standard of Dabigatran etexilate (mesylate). This product is intended for research and analytical applications. Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate mesylate (Standard)
  • HY-P4721
    Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)

    		Thrombin Cardiovascular Disease
    Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
    Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)
  • HY-10264S
    Edoxaban-d6

    DU-176-d6

    		 Factor Xa Thrombin Cardiovascular Disease
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
    Edoxaban-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: